## Note
nid: 1495741324392
model: AnKingOverhaul
tags: #AK_Original_Decks::Step_1::Zanki_Pharmacology, #AK_Step1_v11::!FLAG_THESE_CARDS::!DELETE, #AK_Step1_v11::#B&B::11_Hematology::04_Cancer_Drugs::02_Alkylating_Agents, #AK_Step1_v11::#B&B::19_Renal::05_Other::05_Renal_&_Bladder_Malignancies, #AK_Step1_v11::#FirstAid::10_Hematology_Oncology::05_Pharm::13_Alkylating_Agents, #AK_Step1_v11::#FirstAid::10_Hematology_Oncology::05_Pharm::13_Alkylating_Agents::Cyclophosphamide, #AK_Step1_v11::#OME_banner::Basic_Science::12_Renal, #AK_Step1_v11::#Physeo::09_Pharm::17_Hem/Onc_Pharm::Busulfan_Cyclophosphamide_Ifosfamide_Nitorsureas, #AK_Step1_v11::#Pixorize::02_Biochem::22_Onc_Drugs::07_Cyclophosphamide,_Ifosfamide, #AK_Step1_v11::#SketchyPath::08_Repro_&_GU::05_Male_GU::03_Bladder_Cancer_&_Penile_Disorders, #AK_Step1_v11::#SketchyPharm::08_Antineoplastics::02_Dna_&_Cellular_Division::01_Cyclophosphamide,_ifosfamide,_busulfan,_nitrosoureas_(carmustine,_lomustine,_streptozocin)::zanki_extra, #AK_Step1_v11::^Other::^EXPN, #AK_Step1_v11::^Other::^HighYield::1-HighYield
markdown: false

### Text
<div>
  As a result of <b>Cyclophosphamide</b> metabolites accumulating
  in the {{c2::<b>bladder</b>}}, it is associated with
  {{c1::<b>transitional cell</b>}} <b>carcinoma</b>
</div>

### Extra
<i><img src="paste-235501646774273.jpg"></i>

### Lecture Notes


### Missed Questions


### Pathoma


### Boards and Beyond


### First Aid
<img src="paste-183068686024707.jpg"><img src=
"paste-71386651426819.jpg">

### Sketchy
<div><img src="paste-359858129862657.jpg" class="resizer"><img src=
"paste-ad14b6d0922f1d7fd590079a8c8780ffd0ca15d3.png" class=
"resizer"><img src="clip_image003.jpg" class="resizer"><img src=
"clip_image002.jpg" class="resizer"></div>
<div><img src="Complete%20Sketch_1566160514431.jpg" class=
"resizer"></div>

### Pixorize


### Physeo


### OME
<div class="ome-widget">
  <a href="https://onlinemeded.org/spa/renal?ref=anki"><img src=
  "_OME_AnkiFlashcards_Topic_6.png"></a>
</div>

### Additional Resources


### One by one

